Alethio Therapeutics Raises $90 Million In Series A Funding To Advance Targeted Treatments For Blood Cancers
· pulse2.com · popularity 19/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Alethio Therapeutics, a biotechnology company developing targeted medicines for myeloproliferative neoplasms, has raised $90 million (£67 million) in an oversubscribed Series A financing round. The investment was co-led by Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with additional support from Cancer Research Horizons and the University of Oxford. The post Alethio Therapeutics Raises $90 Million In Series A Funding To Advance Targeted Treatments For Blood Cancers appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.